Esatoglu Sinem Nihal, Hatemi Gulen
Department of Rheumatology, Gaziosmanpasa Training and Research Hospital.
Department of Medicine, Division of Rheumatology, Department of Internal Medicine, Cerrahpasa Medical School, Istanbul University-Cerrahpasa, Istanbul, Turkey.
Curr Opin Rheumatol. 2022 Jan 1;34(1):18-24. doi: 10.1097/BOR.0000000000000852.
The purpose of this review is to summarize the recent advances in Takayasu arteritis (TAK), mainly focusing on pathogenesis, imaging modalities, and management.
Three novel clusters based on angiographic findings were identified in the Indian cohort and replicated in the North American cohorts. Different new imaging modalities have been tried in the assessment of arterial inflammation with promising results. There is more evidence on the long-term use of tocilizumab, but relapses are common. In light of the recent findings on the pathogenesis of TAK, Janus kinase inhibitors seem to be promising.
Improvement in imaging modalities and in our understanding of the disease pathogenesis will allow us to better assess the disease activity and identify effective therapeutic agents.
本综述旨在总结高安动脉炎(TAK)的最新进展,主要聚焦于发病机制、影像学检查方法及治疗。
在印度队列中基于血管造影结果确定了三个新的聚类,并在北美队列中得到验证。已尝试使用不同的新型影像学检查方法评估动脉炎症,结果令人鼓舞。关于托珠单抗的长期使用有了更多证据,但复发很常见。鉴于TAK发病机制的最新发现,Janus激酶抑制剂似乎很有前景。
影像学检查方法的改进以及我们对疾病发病机制的理解,将使我们能够更好地评估疾病活动度并确定有效的治疗药物。